Available Technologies

Browse Penn-owned technologies available for licensing.


Search Results - immunology

3 Results Sort By:
Lipid nanoparticle-based mRNA delivery for CAR T-cell engineering
A library of ionizable lipid nanoparticles (LNPs) was screened for ability to deliver mRNA to T-cells, leading to an optimized LNP formulation for delivery of mRNA to T-cells. This thereby enhances the ability to generate transient chimeric antigen receptor (CAR)-expressing T-cells for cancer immunotherapy.Problem: Chimeric antigen receptor (CAR) T-cells...
Published: 5/4/2020   |   Inventor(s): Margaret Billingsley, Carl June, Nathan Singh, Michael Mitchell
Keywords(s): Bioengineering, COVID-19, Drug Delivery, Immunology, Immunotherapy
Category(s): Therapeutics & Vaccines
Therapeutic targets for T-cell lymphomas and other types of cancer
Interdependence of oncogenic and epigenetic mechanisms in T-cell lymphoma.Technology Overview: Anaplastic large cell lymphoma (ALCL) is a highly malignant type of Non-Hodgkin’s T cell lymphoma in which chromosomal translocation leads to the expression of a fusion oncoprotein Tyrosine Kinase - Nucleophosmin/Anaplastic Lymphoma Kinase or NPM/ALK.Dr....
Published: 3/20/2020   |   Inventor(s): Mariusz Wasik
Keywords(s): Immunology, Oncology
Category(s): Therapeutics & Vaccines
Fully human anti-mesothelin CAR with low immunogenicity for in vivo persistence of anti-tumor engineered T cells
The fully human CAR targets mesothelin, a surface protein overexpressed in several cancer types. P4, a human antibody fragment that binds human mesothelin with high specificity, is fused to T cell signaling domains such as 28z. The T cells engineered to express this CAR are shown to shrink tumors in a mouse model bearing human ovarian tumors overexpressing...
Published: 1/29/2020   |   Inventor(s): Daniel Powell
Keywords(s): Antibody, Autoimmune, Cell Therapy, Immunology, Immunoncology, Oncology
Category(s): Therapeutics & Vaccines